TAbS

TAbS

Database for
Therapeutic Antibodies

Home
Database
Tutorial
Statistics
Contact Us
Login

Home
Database
Tutorial
Statistics
Contact Us
Login

Molecule name (INN, drug code)

Molecular Characteristics:

General Molecular Category^*

Target antigen(s) Click here to view the target list

Format, general category

All
TBD
Full length Ab
Full length Ab conjugate
Fragment
Appended Ig
Fragment-Fc conjugate
Fragment conjugate
Fragment fusion
Fragment-Fc
Full length Ab fusion
Appended Ig fusion
Fragment-Fc fusion
Appended Ig conjugate

Isotype (Fc)

All
TBD
IgG1
IgG4
None
IgG2
IgM
IgG1/4
IgE
IgG2/4
IgG2a/b
IgG2a, IgG2b
IgG3
IgG1/2
IgG2b
IgG1/3
IgG2a

Light chain isotype

All
TBD
lambda
kappa
kappa/lambda
None
kappa, lambda
Vlambda-Ckappa

mAb sequence source

All
mAb - source TBD
mAb humanized
mAb human
mAb humanized/chimeric
mAb chimeric
mAb chimeric/humanized
mAb murine
mAb humanized/human
mAb deimmunized
mAb chimeric/human
mAb murine/rat
mAb human, humanized
mAb primatized

Clinical development

General development status category

All
Clinical
IND
Regulatory review
Approved
Preclinical
Terminated
No development reported
Emergency use
Withdrawn

Most advanced stage of development (global)

Approved
- All
- Approved China
- Approved EU, US, Japan, Australia
- Approved US
- Approved EU, US
- Approved EU, US, Japan, Canada, UK
- Approved EU, China, UKJ
- Approved EU, US, Australia
- Approved EU, US, Japan, UK
- Approved EU, US, Japan, Australia, China
- Approved EU, US, Japan, Australia, UK
- Approved EU, US, China, UK
- Approved US, Japan
- Approved US, Japan, UK
- Approved EU, US, Switzerland, UK
- Approved EU
- Approved EU, US, Japan, Australia, Canada
- Approved US, Japan, China, UK
- Approved EU, US, Japan, Australia, Canada, Switzerland
- Approved EU, US, Australia, China, Russia
- Approved EU, US, Japan, China
- Approved Russia
- Approved US, Canada
- Approved EU, US, Canada, UK, Australia
- Approved US, Australia
- Approved China, India, Cuba
- Approved Argentina, Cuba
- Approved EU, US, Japan, Australia, UK, Canada
- Approved EU, US, Japan, Australia, Canada, UK
- Approved Australia, Canada
- Approved EU, US, Canada, UK, Australia, China
- Approved EU, US, Japan
- Approved Japan
- Approved India
- Approved EU, UK, Australia
- Approved EU, Japan, Australia
- Approved EU, US, Australia, UK
- Approved EU, Australia, South Korea
- Approved US, China
- Approved EU, US, Japan, Canada
- Approved EU, US, Japan, China, Australia
- Approved EU, US, Japan, Australia, Russia
- Approved EU, US, Australia, UK, Switzerland
Clinical
- All
- Phase 1
- Phase 2
- Regulatory review EU
- Phase 1/2
- Phase 3
- Phase 1
- Phase 2/3
- Phase 2 pivotal
- Regulatory review China
Emergency use
- All
- Emergency use authorization
IND
- All
- IND
Preclinical
- All
- Preclinical
Regulatory review
- All
- Regulatory review EU, US, Japan, UK
- Regulatory review China
- Regulatory review US
- Regulatory review EU
- Regulatory review EU, US, Japan, Canada
- Approved China
- Regulatory review EU, US
- Regulatory review EU, Japan
Terminated
- All
- Terminated at Phase 2
- Terminated at Phase 1
- Terminated at Phase 3
- Terminated at Phase 1/2
- Terminated at Phase 2/3
- Terminated at regulatory review
- Withdrawn after Emergency use authorization
- Terminated at regulatory review
Withdrawn
- All
- Withdrawn

Choose column and search by date

Primary therapeutic area

All
Cancer
Immune-mediated / inflammatory disorders
Infectious diseases
Metabolic disorders
Ophthalmic disorders
Neurological disorders
Undisclosed
Muscular disorders
Cardiovascular / hemostasis disorders
Skeletal disorders
Respiratory diseases
None
Other - Intoxication
Cancer, Immune-mediated / inflammatory disorders
Other - Infertility
Other - Kidney disease
Other - Contraception
Immune-mediated / inflammatory disorders, Metabolic disorders
Other - Endocrine
Cancer, Ophthalmic disorders

Location of the company

Asia
- All
- Japan
- China
- Republic of Korea
- Taiwan
- Singapore
- India
Australia
- All
- Australia
Europe
- All
- Germany
- United Kingdom
- Netherlands
- Belgium
- Russia
- France
- Denmark
- Switzerland
- Sweden
- Ireland
- Italy
- Poland
- Finland
- Spain
- Norway
- Slovakia
- Austria
- Czech Republic
Middle East
- All
- Israel
- Iraq
North America
- All
- United States of America
- Canada
- British Virgin Islands
- Republic of Cuba

Free Text Search (search any word in any column)

Click to retrieve records

Reset filters

ℹ

The default selected options display the complete data. Click this button to reset to default.

antibody-society

For queries related to the data, please contact:

The Antibody Society: info@antibodysociety.org

For queries related to the website, please contact:

Puneet Rawat: puneet.rawat@medisin.uio.no

Follow us online

antibody-society

TAbS database is developed on Django, a python-based web framwwork

Curated by: Dr. Silvia Crescioli (The Antibody Society), Dr. Janice Reichert (The Antibody Society)